688 related articles for article (PubMed ID: 18728266)
21. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol.
Saito J; Matsuzawa Y; Ito H; Omura M; Ito Y; Yoshimura K; Yajima Y; Kino T; Nishikawa T
Endocr Res; 2010; 35(4):145-54. PubMed ID: 20958145
[TBL] [Abstract][Full Text] [Related]
22. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P
J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
[TBL] [Abstract][Full Text] [Related]
24. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
[TBL] [Abstract][Full Text] [Related]
25. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
27. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension.
Assadi F
J Nephrol; 2014 Feb; 27(1):51-6. PubMed ID: 24519863
[TBL] [Abstract][Full Text] [Related]
28. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
29. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
30. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
31. The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial.
Dawson J; Quinn TJ; Harrow C; Lees KR; Walters MR
Br J Clin Pharmacol; 2009 Nov; 68(5):662-8. PubMed ID: 19916990
[TBL] [Abstract][Full Text] [Related]
32. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Doria A; Galecki AT; Spino C; Pop-Busui R; Cherney DZ; Lingvay I; Parsa A; Rossing P; Sigal RJ; Afkarian M; Aronson R; Caramori ML; Crandall JP; de Boer IH; Elliott TG; Goldfine AB; Haw JS; Hirsch IB; Karger AB; Maahs DM; McGill JB; Molitch ME; Perkins BA; Polsky S; Pragnell M; Robiner WN; Rosas SE; Senior P; Tuttle KR; Umpierrez GE; Wallia A; Weinstock RS; Wu C; Mauer M;
N Engl J Med; 2020 Jun; 382(26):2493-2503. PubMed ID: 32579810
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension - A randomized crossover study (terao study).
Kojima S; Kojima S; Hifumi A; Soejima H; Ogawa H
Int J Cardiol; 2016 Dec; 224():437-439. PubMed ID: 27701062
[No Abstract] [Full Text] [Related]
36. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski JS; Clark MA
Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
[TBL] [Abstract][Full Text] [Related]
37. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
38. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
Wong GW; Laugerotte A; Wright JM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol treatment reduces arterial wave reflection in stroke survivors.
Khan F; George J; Wong K; McSwiggan S; Struthers AD; Belch JJ
Cardiovasc Ther; 2008; 26(4):247-52. PubMed ID: 19035875
[TBL] [Abstract][Full Text] [Related]
40. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
Doehner W; Schoene N; Rauchhaus M; Leyva-Leon F; Pavitt DV; Reaveley DA; Schuler G; Coats AJ; Anker SD; Hambrecht R
Circulation; 2002 Jun; 105(22):2619-24. PubMed ID: 12045167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
